A DNA methylation signature for the prediction of tumour recurrence in stage II colorectal cancer.

ABSTRACT:

Background

A major challenge in stage II colorectal carcinoma is to identify patients with increased risk of recurrence. Biomarkers that distinguish patients with poor prognosis from patients without recurrence are currently lacking. This study aims to develop a robust DNA methylation classifier that allows the prediction of recurrence and chemotherapy benefit in patients with stage II colorectal cancer. We performed a genome-wide DNA methylation capture sequencing in 243 stage II colorectal carcinoma samples and identified a relapse-specific DNA methylation signature consisting of eight CpG sites.

Methods

Two hundred and forty-three patients with stage II CRC were enrolled in this study. In order to select differential methylation sites among recurrence and non-recurrence s

SUBMITTER: Li M 

PROVIDER: S-EPMC10133253 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature